543298 Stock Overview
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vineet Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹50.00 |
| 52 Week High | ₹88.95 |
| 52 Week Low | ₹46.98 |
| Beta | -0.28 |
| 11 Month Change | -9.01% |
| 3 Month Change | -20.36% |
| 1 Year Change | -28.11% |
| 33 Year Change | -31.08% |
| 5 Year Change | n/a |
| Change since IPO | 6.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543298 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.9% | 2.3% | 2.4% |
| 1Y | -28.1% | 43.8% | 29.5% |
Return vs Industry: 543298 underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 543298 underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| 543298 volatility | |
|---|---|
| 543298 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 543298 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 543298's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 79 | n/a | vineetlabs.co.in |
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.
Vineet Laboratories Limited Fundamentals Summary
| 543298 fundamental statistics | |
|---|---|
| Market cap | ₹463.26m |
| Earnings (TTM) | -₹41.01m |
| Revenue (TTM) | ₹1.13b |
0.4x
P/S Ratio-11.3x
P/E RatioIs 543298 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543298 income statement (TTM) | |
|---|---|
| Revenue | ₹1.13b |
| Cost of Revenue | ₹892.35m |
| Gross Profit | ₹241.85m |
| Other Expenses | ₹282.86m |
| Earnings | -₹41.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.45 |
| Gross Margin | 21.32% |
| Net Profit Margin | -3.62% |
| Debt/Equity Ratio | 131.9% |
How did 543298 perform over the long term?
See historical performance and comparison